^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SYS6010

    i
    Other names: CPO-301, SYS 6010, SYS-6010, SYS6010, CPO301, CPO 301
    Associations

    News

    Trials
    Company:
    CSPC Pharma
    Drug class:
    Topoisomerase I inhibitor, EGFR-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    3d
    An open-label, multicenter, phase II study to evaluate the efficacy and safety of SYS6010 combined with enlonstobart in the recurrent or metastatic head and neck squamous cell carcinoma (ChiCTR2500112871)
    P2, N=70, Not yet recruiting, Shanghai East Hospital, Tongji University(Shanghai East Hospital); Shanghai East Hospital, Tongji University(Shanghai East Hospital)
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Enshuxing (enlonstobart) • SYS6010
    3d
    A Study of SYS6010 Combined with Osimertinib versus Osimertinib alone as Neoadjuvant Therapy for Patients with EGFRm Resectable Non-squamous Non-small Cell Lung Cancer (ChiCTR2500113154)
    P2, N=120, Not yet recruiting, Shanghai Chest Hospital; Shanghai Pulmonary Hospital; CSPC Megalith Biopharmaceutical Co., Ltd
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • SYS6010 • simmitinib (SYHA1817)
    3d
    Phase II/III Trial of SYS6010 plus Enlonstobart Injection ± Chemotherapy in Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ChiCTR2500112440)
    P2/3, N=737, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    EGFR expression
    |
    cisplatin • paclitaxel • 5-fluorouracil • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • leucovorin calcium • Enshuxing (enlonstobart) • SYS6010
    3d
    A phase Ib/II clinical trial on the safety and efficacy of sirolimus (albumin-bound) combined with different ADCs in patients with advanced solid tumors (ChiCTR2500111937)
    P1, N=444, Not yet recruiting, Fudan University Shanghai Cancer Center; CSPC Zhongqi Pharmaceutical Technology Co., Ltd.
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • CD276 (CD276 Molecule) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    HER-2 negative • HER-2 expression • EGFR expression
    |
    sirolimus • trastuzumab envedotin (DP303c) • SYS6010 • sirolimus for injection (albumin-bound) (SRL-HSA)
    5d
    SYNSTAR-02: A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P3, N=450, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • SYS6010 • simmitinib (SYHA1817)
    8d
    SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=70, Recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    Enshuxing (enlonstobart) • SYS6010
    2ms
    A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P2 trial
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • SYS6010
    2ms
    SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=70, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P2 trial
    |
    Enshuxing (enlonstobart) • SYS6010
    2ms
    A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. (clinicaltrials.gov)
    P2/3, N=737, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P2/3 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    EGFR expression
    |
    cisplatin • paclitaxel • 5-fluorouracil • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • Enshuxing (enlonstobart) • SYS6010
    2ms
    A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=444, Recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    New P1/2 trial
    |
    sirolimus • trastuzumab envedotin (DP303c) • SYS6010
    3ms
    Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01） (clinicaltrials.gov)
    P3, N=380, Recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • carboplatin • pemetrexed • SYS6010
    6ms
    A Phase Ⅰb/Ⅲ Clinical Study of SYS6010 in combination with Osimertinib in patients with locally advanced or metastatic NSCLC (ChiCTR2500106103)
    P1, N=116, Recruiting, Shanghai Chest Hospital; Shanghai Chest Hospital
    New P1 trial
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • SYS6010